8-K: Picard Medical CEO to Present Emperor TAH Data in Germany

Picard Medical's CEO, Patrick NJ Schnegelsberg, will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference in Frankfurt, Germany, on December 6, 2025.

Summary

• Picard Medical, Inc. announced that its CEO, Patrick NJ Schnegelsberg, will present data on the fully implantable Emperor Total Artificial Heart (TAH).
• The presentation is scheduled for the CSI Focus D-HF (Device Therapies in Heart Failure) conference in Frankfurt, Germany.
• The conference runs from December 5-6, 2025, with the specific presentation on Saturday, December 6, 2025, from 13:00 to 13:45 CET.
• Picard Medical is the parent company of SynCardia Systems LLC, which manufactures the SynCardia Total Artificial Heart (STAH), the world's first total artificial heart approved by both the U.S. FDA and Health Canada.
• The SynCardia Total Artificial Heart has been implanted over 2,100 times at hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally.

Sentiment

Score: 7

Explanation: The announcement is positive as it highlights the company's continued innovation with the Emperor TAH and its engagement with the medical community at a prominent conference. It reinforces the company's leadership in artificial heart technology. No negative news or risks were disclosed.

Positives

• The CEO's presentation at CSI Focus D-HF, a leading global workshop, enhances Picard Medical's visibility and engagement within the heart failure device therapy community.
• Presenting data on the fully implantable Emperor Total Artificial Heart indicates ongoing innovation and development in the company's product pipeline.
• SynCardia Systems LLC maintains a strong market position as the leader with the only commercially available total artificial heart technology approved by both the U.S. FDA and Health Canada.
• The SynCardia Total Artificial Heart's extensive use, with over 2,100 implants in 27 countries, demonstrates significant clinical adoption and global reach.

Future Outlook

The presentation of data on the fully implantable Emperor Total Artificial Heart at a prominent international conference suggests Picard Medical's continued focus on advancing its heart failure device solutions and potentially expanding its product offerings beyond the currently commercialized SynCardia Total Artificial Heart.

Management Comments

• Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference.

Industry Context

The announcement positions Picard Medical within the rapidly evolving field of device-based therapies for heart failure. The CSI Focus D-HF conference is a key event for interventional cardiologists, engineers, and industry innovators, indicating Picard Medical's engagement with leading experts and its commitment to staying at the forefront of heart failure treatment advancements. The focus on a 'fully implantable' artificial heart suggests a move towards less invasive and potentially more patient-friendly solutions, aligning with broader trends in medical device innovation.

Comparison to Industry Standards

• SynCardia Systems LLC is highlighted as the leader with the only commercially available total artificial heart technology approved by both the U.S. FDA and Health Canada, setting a high standard for regulatory achievement in the industry.
• With over 2,100 implants performed across 27 countries, the SynCardia Total Artificial Heart is described as the most widely used and extensively studied artificial heart globally, indicating a strong market presence and clinical validation compared to potential competitors in the artificial heart space.
• The presentation of the Emperor Total Artificial Heart at CSI Focus D-HF, a leading global workshop, demonstrates Picard Medical's participation alongside other innovators exploring next-generation heart failure device solutions, including ventricular restoration, neuromodulation, interatrial shunts, and implantable monitoring systems.

Stakeholder Impact

• Shareholders: Increased visibility and potential positive sentiment due to the CEO's presentation at a major conference, showcasing innovation.
• Patients: Potential for future advanced treatment options with the fully implantable Emperor Total Artificial Heart.
• Medical Community: Opportunity to learn about new data and advancements in total artificial heart technology.

Next Steps

• CEO Patrick NJ Schnegelsberg to present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference on December 6, 2025.

Key Dates

Recommendation

The announcement is positive, highlighting innovation and market leadership, which could generate positive sentiment. However, it's an announcement of a presentation, not a new product launch or significant financial update. While it reinforces the company's position, it doesn't provide new fundamental data that would warrant a 'buy' or 'strong buy' without further analysis of the presented data or financial performance. The existing market position and ongoing development support maintaining current positions.

Keywords

Picard Medical, SynCardia, Total Artificial Heart, Emperor TAH, Heart Failure, Medical Devices, Cardiology, CSI Focus D-HF, FDA Approved, Health Canada Approved